Regeneron Pharmaceuticals... (REGN)
undefined
undefined%
At close: undefined

Company Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.

It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC.

The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc. logo
Country United States
IPO Date Apr 2, 1991
Industry Biotechnology
Sector Healthcare
Employees 14,165
CEO Dr. Leonard S. Schleifer M.D., Ph.D.

Contact Details

Address:
777 Old Saw Mill River Road
Tarrytown, New York
United States
Website https://www.regeneron.com

Stock Details

Ticker Symbol REGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000872589
CUSIP Number 75886F107
ISIN Number US75886F1075
Employer ID 13-3444607
SIC Code 2834

Key Executives

Name Position
Dr. Leonard S. Schleifer M.D., Ph.D. Co-Founder, President, Chief Executive Officer & Co-Chairman
Bob McCowan Senior Vice President of IT & Chief Information Officer
Christopher R. Fenimore CPA Senior Vice President of Finance & Chief Financial Officer
Daniel P. Van Plew Executive Vice President and GM of Industrial Operations & Product Supply
Dr. Andrew J. Murphy Ph.D. Executive Vice President of Research
Dr. George D. Yancopoulos M.D., Ph.D. Co-Founder, President, Chief Scientific Officer & Co-Chairman
Joseph J. LaRosa J.D. Executive Vice President, General Counsel & Secretary
Melissa Lozner Senior Vice President & Chief Compliance Officer
Patrice Gilooly Senior Vice President of Quality Assurance & Operations
Ryan Crowe Senior Vice President of Investor Relations & Strategic Analysis

Latest SEC Filings

Date Type Title
Dec 10, 2024 4 Filing
Dec 10, 2024 4 Filing
Dec 10, 2024 4 Filing
Dec 10, 2024 4 Filing
Dec 10, 2024 4 Filing
Dec 10, 2024 4 Filing
Dec 10, 2024 4 Filing
Nov 12, 2024 4 Filing
Nov 05, 2024 4 Filing
Oct 31, 2024 S-3ASR Automatic shelf registration statement of securiti...